A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Radalbuvir (Primary) ; Sofosbuvir (Primary) ; Velpatasvir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELECTRON-2
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Nov 2015 According to media release of Gilead Sciences, results were published.
    • 12 Nov 2015 Results published in the Media Release
    • 12 Nov 2015 According to Gilead Sciences media release, U.S. Food and Drug Administration (FDA) approved Harvoni (ledipasvir/sofosbuvir) for the expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection. The supplemental new drug application sNDA approval was granted on the basis of data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top